{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T15:17:12Z","timestamp":1777907832805,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int Pharmacopsychiatry"],"abstract":"<jats:p>In this paper, the efficacy of lithium therapy in the treatment of tardive\ndyskinesia is reviewed. It is noted that most of the published papers on this topic are\nanecdotal and single case reports with contradictory results. The well-designed studies\nindicate that lithium is useful in certain tardive dyskinesia patients and that the red\nblood cell lithium level may be related to the therapeutic response. Therefore, on the\nbasis of the available information, we conclude that routine clinical application of\nlithium in the treatment of tardive dyskinesia is not warranted. However, further\nevaluation of lithium in the treatment of tardive dyskinesia and identification of the\nresponders are extremely useful. In addition, as suggested by animal studies, the prophylactic\nvalue of this agent against tardive dyskinesia needs exploration.<\/jats:p>","DOI":"10.1159\/000468453","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:20:33Z","timestamp":1502472033000},"page":"301-308","source":"Crossref","is-referenced-by-count":7,"title":["Lithium Carbonate in the Treatment of Movement Disorders"],"prefix":"10.1159","author":[{"given":"R.","family":"Yassa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ananth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["International Pharmacopsychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000468453","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T13:49:01Z","timestamp":1777643341000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000468453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000468453","archive":["Portico"],"relation":{},"ISSN":["0020-8272","2504-2580"],"issn-type":[{"value":"0020-8272","type":"print"},{"value":"2504-2580","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}